Episode 2 of 3 - Moving Towards Fixed-Duration Therapy in CLL and SLL
Tracking # 20-1042272
Free
There are no ratings for this course
Learn moreCourse overview
The emergence of fixed-duration therapy, which combines two or more drugs within a set timeframe, has shown promise for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, it leads to many clinical questions regarding establishing an optimal combinational therapy and sequence to best fit the needs of the patient. Join us for the second episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement as our experts and special guests discuss the implications of the new data in fixed-duration therapy, as well as strategies to promote inclusive clinical trial participation.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Medicine
Medical Doctor
Florida Board of Pharmacy
Pharmacist
Disclosure statements
FACULTY DISCLOSURES
Planner/Presenter
Sanjay Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Advisory Board/Consultant: Daiichi Sankyo and Guardant 360
Speakers’ Bureau: AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus
Stock Ownership: Phenomune and xCures
Independent Contractor: xCures
Planner/Presenter
Nicole Lamanna, MD
Associate Attending, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, NY
Advisory Board/Consultant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Janssen, and Pharmacyclics
Research Grant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Octapharma, Oncternal Therapeutics, MingSight, and TG Therapeutics
Planner/Presenter
Raajit K. Rampal, MD, PhD
Associate Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Advisory Board/Consultant for: AbbVie, Blueprint Medicines, Celgene/Bristol Myers Squibb, Constellation, CTI BioPharma, Disc Medicine, Galecto, Incyte, Novartis, Pharmaessentia, Promedior, Servier, Sierra Oncology/GlaxoSmithKline, Stemline, and Sumitomo Dainippon,
Research Grant for: Constellation, Incyte, Ryvu, Stemline, Zentalis
Planner/Presenter
Erika Pomares, LMSW
Senior Manager, Patient & Community Outreach
The Leukemia & Lymphoma Society
Rye Brook, NY
Erika Pomares, LMSW, has no relevant financial relationship with ineligible companies to disclose for this educational activity.
Patient/Planner/Presenter
Greg Simon
Advisory Board/Consultant for: Day One Therapeutics, Vaxart, WinSanTor
Stock Ownership: Day One Therapeutics
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.
SUPPORT STATMENT
Supported by educational grants from Genentech, a member of the Roche Group and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.